• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

蛋白酶和蛋白酶激活受体-2 在特应性皮炎发病机制中的作用。

Protease and protease-activated receptor-2 signaling in the pathogenesis of atopic dermatitis.

机构信息

Department of Dermatology, Yonsei University College of Medicine, Gangnam Severance Hospital, 712 Eonju-ro, Gangnam-gu, Seoul 135-720, Korea.

出版信息

Yonsei Med J. 2010 Nov;51(6):808-22. doi: 10.3349/ymj.2010.51.6.808.

DOI:10.3349/ymj.2010.51.6.808
PMID:20879045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2995962/
Abstract

Proteases in the skin are essential to epidermal permeability barrier homeostasis. In addition to their direct proteolytic effects, certain proteases signal to cells by activating protease-activated receptors (PARs), the G-protein-coupled receptors. The expression of functional PAR-2 on human skin and its role in inflammation, pruritus, and skin barrier homeostasis have been demonstrated. Atopic dermatitis (AD) is a multifactorial inflammatory skin disease characterized by genetic barrier defects and allergic inflammation, which is sustained by gene-environmental interactions. Recent studies have revealed aberrant expression and activation of serine proteases and PAR-2 in the lesional skin of AD patients. The imbalance between proteases and protease inhibitors associated with genetic defects in the protease/protease inhibitor encoding genes, increase in skin surface pH, and exposure to proteolytically active allergens contribute to this aberrant protease/ PAR-2 signaling in AD. The increased protease activity in AD leads to abnormal desquamation, degradation of lipid-processing enzymes and antimicrobial peptides, and activation of primary cytokines, thereby leading to permeability barrier dysfunction, inflammation, and defects in the antimicrobial barrier. Moreover, up-regulated proteases stimulate PAR-2 in lesional skin of AD and lead to the production of cytokines and chemokines involved in inflammation and immune responses, itching sensation, and sustained epidermal barrier perturbation with easier allergen penetration. In addition, PAR-2 is an important sensor for exogenous danger molecules, such as exogenous proteases from various allergens, and plays an important role in AD pathogenesis. Together, these findings suggest that protease activity or PAR-2 may be a future target for therapeutic intervention for the treatment of AD.

摘要

皮肤中的蛋白酶对于表皮渗透性屏障的稳态至关重要。除了直接的蛋白水解作用外,某些蛋白酶还通过激活蛋白酶激活受体(PARs)即 G 蛋白偶联受体向细胞发出信号。已经证明人皮肤中功能性 PAR-2 的表达及其在炎症、瘙痒和皮肤屏障稳态中的作用。特应性皮炎(AD)是一种多因素炎症性皮肤病,其特征是遗传屏障缺陷和过敏炎症,由基因-环境相互作用维持。最近的研究揭示了丝氨酸蛋白酶和 PAR-2 在 AD 患者皮损皮肤中的异常表达和激活。与蛋白酶/蛋白酶抑制剂编码基因遗传缺陷相关的蛋白酶和蛋白酶抑制剂之间的失衡、皮肤表面 pH 值增加以及暴露于具有蛋白水解活性的变应原,导致 AD 中这种异常的蛋白酶/PAR-2 信号传导。AD 中蛋白酶活性的增加导致异常的脱屑、脂质处理酶和抗菌肽的降解以及原初细胞因子的激活,从而导致渗透性屏障功能障碍、炎症和抗菌屏障缺陷。此外,上调的蛋白酶刺激 AD 皮损皮肤中的 PAR-2,并导致参与炎症和免疫反应、瘙痒感觉以及持续的表皮屏障扰动的细胞因子和趋化因子的产生,更容易使变应原穿透。此外,PAR-2 是外来危险分子(如各种变应原的外来蛋白酶)的重要传感器,在 AD 的发病机制中发挥重要作用。综上所述,蛋白酶活性或 PAR-2 可能成为 AD 治疗干预的未来靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/275c/2995962/7b2b737224ce/ymj-51-808-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/275c/2995962/5dc8a074766b/ymj-51-808-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/275c/2995962/19125df85237/ymj-51-808-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/275c/2995962/d5e9cf617491/ymj-51-808-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/275c/2995962/7b2b737224ce/ymj-51-808-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/275c/2995962/5dc8a074766b/ymj-51-808-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/275c/2995962/19125df85237/ymj-51-808-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/275c/2995962/d5e9cf617491/ymj-51-808-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/275c/2995962/7b2b737224ce/ymj-51-808-g004.jpg

相似文献

1
Protease and protease-activated receptor-2 signaling in the pathogenesis of atopic dermatitis.蛋白酶和蛋白酶激活受体-2 在特应性皮炎发病机制中的作用。
Yonsei Med J. 2010 Nov;51(6):808-22. doi: 10.3349/ymj.2010.51.6.808.
2
Mite and cockroach allergens activate protease-activated receptor 2 and delay epidermal permeability barrier recovery.螨虫和蟑螂过敏原激活蛋白酶激活受体2并延缓表皮通透性屏障的恢复。
J Invest Dermatol. 2008 Aug;128(8):1930-9. doi: 10.1038/jid.2008.13. Epub 2008 Feb 28.
3
Role of PAR-2 in Neuroimmune Communication and Itch蛋白酶激活受体-2在神经免疫通讯及瘙痒中的作用
4
Protease-Activated Receptor-2 Regulates Neuro-Epidermal Communication in Atopic Dermatitis.蛋白酶激活受体 2 调控特应性皮炎的神经表皮通讯。
Front Immunol. 2020 Aug 12;11:1740. doi: 10.3389/fimmu.2020.01740. eCollection 2020.
5
Protease activity enhances production of thymic stromal lymphopoietin and basophil accumulation in flaky tail mice.蛋白酶活性增强胸腺基质淋巴生成素的产生和花斑尾鼠嗜碱性粒细胞的聚集。
Am J Pathol. 2013 Mar;182(3):841-51. doi: 10.1016/j.ajpath.2012.11.039. Epub 2013 Jan 17.
6
Aberrant serine protease activities in atopic dermatitis.特应性皮炎中的丝氨酸蛋白酶活性异常。
J Dermatol Sci. 2022 Jul;107(1):2-7. doi: 10.1016/j.jdermsci.2022.06.004. Epub 2022 Jun 28.
7
Antagonism of Protease Activated Receptor-2 by GB88 Reduces Inflammation Triggered by Protease Allergen Tyr-p3.蛋白酶激活受体-2 拮抗剂 GB88 可减少蛋白酶变应原 Tyr-p3 引发的炎症。
Front Immunol. 2021 Sep 8;12:557433. doi: 10.3389/fimmu.2021.557433. eCollection 2021.
8
Netherton syndrome: skin inflammation and allergy by loss of protease inhibition. Netherton 综合征:蛋白酶抑制丧失导致的皮肤炎症和过敏。
Cell Tissue Res. 2013 Feb;351(2):289-300. doi: 10.1007/s00441-013-1558-1. Epub 2013 Jan 24.
9
First report in a dog model of atopic dermatitis: expression patterns of protease-activated receptor-2 and thymic stromal lymphopoietin.特应性皮炎犬模型的首次报告:蛋白酶激活受体-2和胸腺基质淋巴细胞生成素的表达模式
Vet Dermatol. 2015 Jun;26(3):180-5, e36-7. doi: 10.1111/vde.12203. Epub 2015 May 4.
10
Clinically uninvolved but not healthy-The skin of patients with atopic dermatitis is primed for itch and inflammation.临床无病灶,但不健康——特应性皮炎患者的皮肤容易瘙痒和发炎。
J Eur Acad Dermatol Venereol. 2024 Jun;38(6):1089-1100. doi: 10.1111/jdv.19694. Epub 2023 Dec 8.

引用本文的文献

1
Unlocking the molecular pathway of atopic dermatitis: journey so far and roads ahead.揭示特应性皮炎的分子途径:迄今为止的历程与未来之路。
Inflammopharmacology. 2025 Aug 18. doi: 10.1007/s10787-025-01900-0.
2
Integrative systems biology framework discovers common gene regulatory signatures in mechanistically distinct inflammatory skin diseases.整合系统生物学框架在机制上不同的炎症性皮肤病中发现了共同的基因调控特征。
NPJ Syst Biol Appl. 2025 Feb 27;11(1):21. doi: 10.1038/s41540-025-00498-x.
3
The Therapeutic Potential of Kiwi Extract as a Source of Cysteine Protease Inhibitors on DNCB-Induced Atopic Dermatitis in Mice and Human Keratinocyte HaCaT Cells.

本文引用的文献

1
Enhanced scratching evoked by PAR-2 agonist and 5-HT but not histamine in a mouse model of chronic dry skin itch.PAR-2 激动剂和 5-HT 而非组胺增强慢性干燥性皮肤瘙痒小鼠模型中的搔抓反应。
Pain. 2010 Nov;151(2):378-383. doi: 10.1016/j.pain.2010.07.024. Epub 2010 Aug 14.
2
Is the filaggrin-histidine-urocanic acid pathway essential for stratum corneum acidification?聚丝蛋白-组氨酸-尿刊酸途径对于角质层酸化是否必不可少?
J Invest Dermatol. 2010 Aug;130(8):2141-4. doi: 10.1038/jid.2010.74. Epub 2010 Apr 8.
3
Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing.
猕猴桃提取物作为半胱氨酸蛋白酶抑制剂来源对二硝基氯苯诱导的小鼠特应性皮炎及人角质形成细胞HaCaT细胞的治疗潜力
Int J Mol Sci. 2025 Feb 12;26(4):1534. doi: 10.3390/ijms26041534.
4
Update on protease-activated receptor 2 in inflammatory and autoimmune dermatological diseases.蛋白酶激活受体 2 在炎症性和自身免疫性皮肤病中的研究进展。
Front Immunol. 2024 Sep 19;15:1449126. doi: 10.3389/fimmu.2024.1449126. eCollection 2024.
5
Protease-Activated Receptor 2 in inflammatory skin disease: current evidence and future perspectives.蛋白酶激活受体 2 在炎症性皮肤病中的作用:现有证据和未来展望。
Front Immunol. 2024 Sep 5;15:1448952. doi: 10.3389/fimmu.2024.1448952. eCollection 2024.
6
Granzymes in health and diseases: the good, the bad and the ugly.健康与疾病中的颗粒酶:善、恶与丑
Front Immunol. 2024 Apr 5;15:1371743. doi: 10.3389/fimmu.2024.1371743. eCollection 2024.
7
Unraveling the skin; a comprehensive review of atopic dermatitis, current understanding, and approaches.揭开皮肤之谜:特应性皮炎的全面综述、现有认识和方法。
Front Immunol. 2024 Mar 4;15:1361005. doi: 10.3389/fimmu.2024.1361005. eCollection 2024.
8
Alpha-Tryptase as a Risk-Modifying Factor for Mast Cell-Mediated Reactions.α-胰凝乳蛋白酶作为肥大细胞介导反应的风险修饰因子。
Curr Allergy Asthma Rep. 2024 Apr;24(4):199-209. doi: 10.1007/s11882-024-01136-y. Epub 2024 Mar 9.
9
Improvement in Cutaneous Conditions Can Benefit Some Health Conditions in the Elderly.改善皮肤状况可以有益于老年人的一些健康状况。
Clin Interv Aging. 2023 Dec 1;18:2031-2040. doi: 10.2147/CIA.S430552. eCollection 2023.
10
Papain as a Potential New Experimental Model of Non-histaminergic Itch.木瓜蛋白酶作为一种潜在的非组胺能性瘙痒新实验模型。
Acta Derm Venereol. 2022 Oct 4;102:adv00786. doi: 10.2340/actadv.v102.2693.
弹性蛋白酶 2 在人类和小鼠表皮中表达,并通过丝聚蛋白和脂质处理异常损害 Netherton 综合征的皮肤屏障功能。
J Clin Invest. 2010 Mar;120(3):871-82. doi: 10.1172/JCI41440. Epub 2010 Feb 22.
4
Kallikrein expression and cathelicidin processing are independently controlled in keratinocytes by calcium, vitamin D(3), and retinoic acid.钙、维生素 D(3) 和维甲酸可独立调控角质形成细胞中激肽释放酶的表达和抗菌肽的加工。
J Invest Dermatol. 2010 May;130(5):1297-306. doi: 10.1038/jid.2009.435. Epub 2010 Jan 21.
5
Dual effect of the novel peptide antagonist K-14585 on proteinase-activated receptor-2-mediated signalling.新型肽类拮抗剂 K-14585 对蛋白酶激活受体-2 介导的信号转导的双重作用。
Br J Pharmacol. 2009 Dec;158(7):1695-704. doi: 10.1111/j.1476-5381.2009.00415.x.
6
Staphylococcus aureus extracellular protease causes epidermal barrier dysfunction.金黄色葡萄球菌细胞外蛋白酶导致表皮屏障功能障碍。
J Invest Dermatol. 2010 Feb;130(2):614-7. doi: 10.1038/jid.2009.257. Epub 2009 Oct 8.
7
The emerging roles of serine protease cascades in the epidermis.丝氨酸蛋白酶级联反应在表皮中的新作用。
Trends Biochem Sci. 2009 Sep;34(9):453-63. doi: 10.1016/j.tibs.2009.08.001. Epub 2009 Aug 31.
8
Novel antagonists for proteinase-activated receptor 2: inhibition of cellular and vascular responses in vitro and in vivo.新型蛋白酶激活受体 2 拮抗剂:体外和体内抑制细胞和血管反应。
Br J Pharmacol. 2009 Sep;158(1):361-71. doi: 10.1111/j.1476-5381.2009.00342.x.
9
LEKTI-1 in sickness and in health.疾病与健康状态下的LEKTI-1
Int J Cosmet Sci. 2009 Aug;31(4):247-54. doi: 10.1111/j.1468-2494.2009.00516.x. Epub 2009 May 13.
10
The cystatin M/E-controlled pathway of skin barrier formation: expression of its key components in psoriasis and atopic dermatitis.胱抑素M/E调控的皮肤屏障形成途径:其关键成分在银屑病和特应性皮炎中的表达
Br J Dermatol. 2009 Aug;161(2):253-64. doi: 10.1111/j.1365-2133.2009.09156.x. Epub 2009 Apr 24.